EC
DAWN

EntryPoint Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

EntryPoint Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,254
Closed -$408K – 782
2024
Q3 		$408K Buy
+29,254
New +$417K 0.23% 117
2024
Q2 		– Sell
-582
Closed -$9.62K – 1046
2024
Q1 		$9.62K Buy
+582
New +$8.71K 0.01% 1240

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

EntryPoint Capital's DAWN Position: Q4 2024 in Review

EntryPoint Capital sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 29,254 shares — an estimated $408K sold.

EntryPoint Capital first reported a position in DAWN in Q1 2024 and held it in 2 quarters. The position peaked at $408K in Q3 2024. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • EntryPoint Capital reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 29,254 Day One Biopharmaceuticals shares in Q4 2024, an estimated $408K.
  • EntryPoint Capital first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's Day One Biopharmaceuticals position peaked at $408K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.